PETERSON TYCHO
Known title: Chief Financial OfficerCIK: 0001927856
Associated companies
Transaction History
| ADPT | ▼ Sell | Open Market | 15,456 | $53K | 3/5/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 147,790 | $0 | 3/4/2024 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 134,961 | $985K | 6/20/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 70,000 | $570K | 6/20/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 64,961 | $529K | 6/20/2023 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 14,328 | $105K | 6/15/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 14,328 | $122K | 6/15/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 55,672 | $475K | 6/15/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 38,000 | $272K | 6/2/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 118,203 | $0 | 3/6/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 374,688 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.